EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

National HealthCare Corporation (NHC) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of National HealthCare Corporation $158, price $225, upside -29.9%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US6359061008

NH National HealthCare Corporation logo Broad data Sep 23, 2026

National HealthCare Corporation

NHC · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $157.66 · Overvalued (−30%)
✓Quality 72/100
✓Healthy Growth (revenue 5y +9.0 %/yr)
!Thin margins · 8.1% net margin (TTM)
✓Low debt · generates free cash flow
·1.14% dividend yield
!Mixed vs. peers (6/15)
!Moderate moat 46/100
!Insider activity 40/100
!Weak on future: 11 out of 100
!Weak on dividend: 23 out of 100
Watch National HealthCare Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$236.75 $48.06 Fair Value $157.66 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $48.06 – $236.75 · fair‑value band $114.27 – $196.69 · the $224.87 price screens above the $157.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow National HealthCare in your weekly email

Every Wednesday you see whether National HealthCare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. It operates through two segments: Inpatient and Homecare and Hospice Services.

Show more

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. It operates through two segments: Inpatient and Homecare and Hospice Services. The company's skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. It provides medical specialty units comprise memory care units and sub-acute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, the company offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

Stock analysis

National HealthCare Corporation (NHC) currently trades at $224.87, while our model-based Fair Value estimate is $157.66, implying the stock looks roughly 42.6% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $154.86 per share, and 0 of the 26 models we run sit above the $224.87 price.

Bear case: the Dividend Discount group reads lowest at $33.33, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $114.27 (bear) to $196.69 (bull), the price of $224.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

National HealthCare Corporation reported revenue of $1.5B in FY2025 versus $1.0B in FY2021, a compound +10.6%/yr. Reported net income was $120M in FY2025, compounding −3.5%/yr from FY2021.

Key figures

Market cap $3.5B · P/E ratio 28.6 · P/S ratio 2.27 · EPS (TTM) $7.87 · Dividend yield 1.1% · Net margin 7.9% · Return on equity 12.0% · Return on assets (EBIT) 5.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 5% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −30%, NHC screens richer than that median.

Fair Value models

Bear $114.27 Fair Value $157.66 Bull $196.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($3.88 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $107.38 $154.86 $221.84 80
Growth DCF $109.45 $152.29 $209.57 79
Owner Earnings $93.92 $135.17 $193.34 77
All 26 models by family
DCF Models
FCF DCF $107.38 $154.86 $221.84 80
Owner Earnings $93.92 $135.17 $193.34 77
5Y Revenue Exit $92.58 $137.15 $192.44 73
5Y EBITDA Exit $113.16 $174.62 $244.35 75
5Y P/E Exit $113.25 $174.78 $237.37 71
10Y Revenue Exit $94.89 $135.68 $187.29 67
10Y EBITDA Exit $109.94 $160.74 $225.05 68
10Y P/E Exit $110.00 $160.84 $219.97 64
Earnings-Based
Graham-Dodd $52.25 $140.94 $184.57 65
Lynch FV $27.59 $39.42 $51.24 61
PEG = 1.0 $27.59 $39.42 $51.24 57
EPV $65.33 $74.86 $83.07 74
Dividend Discount
Gordon GGM $21.76 $43.36 $65.66 67
DDM Multi-Stage $21.76 $33.33 $45.14 66
Multiples
P/E Multiple $126.78 $169.04 $211.30 63
P/S Multiple $97.97 $130.62 $163.28 58
P/B Multiple $97.97 $130.62 $163.28 55
EV/EBIT $122.12 $161.15 $200.18 66
EV/EBITDA $131.65 $173.86 $216.07 67
EV/Revenue $88.60 $124.41 $160.23 54
Asset-Based
NCAV (Graham) $34.21 $45.84 $68.42 54
Growth DCF
Growth DCF $109.45 $152.29 $209.57 79
Rev-Margin DCF $92.58 $138.13 $188.80 73
Economic Profit
Residual Income $61.18 $69.38 $118.57 74
ROIC Compounder $65.33 $77.64 $93.24 72
Growth Earnings
Growth-Adj P/E $99.60 $142.29 $184.98 67

Open the full fair value analysis →

Notify me when NHC reaches fair value

Put NHC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 72/100

Of which business quality 73 · Market factors (momentum, volatility) 84

Profitability 63
Margins and returns on capital today
Quality Growth 77
Are margins and returns improving?
Cashflow 61
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 84
Price trend over the last 3–12 months (market factor)
52W Momentum 95
Distance to the 52-week high (market factor)
Net Issuance 78
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic). Over 10 years: +5.2% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+24.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.0%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12% vs 8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 10%
2025 sits 77% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.3% a year for the price.

NHC screens 43% overvalued. Compare with HCA Healthcare, Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (88 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare National HealthCare Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks

Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 72 · Top 25%
Fair Value upside −30% · Below median
Profitability
Return on equity (TTM) 12% · Above median
Return on assets 5% · Above median
Net margin (TTM) 8% · Above median
Operating margin (TTM) 8% · Below median
Growth and dividend
Revenue growth 2% · Below median
Dividend yield (TTM) 1.1% · Below median
Balance sheet
Debt / equity 0.03× · Lowest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 28.6× · Pricier than median
P/B 3.29× · Priciest 25%
P/S (TTM) 2.31× · Priciest 25%
P/FCF 23.7× · Priciest 25%
EV/EBITDA 19.6× · Priciest 25%
PEG 0.82× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)11 · sector 29
PAST (return on equity)48 · sector 31
HEALTH (low debt)99 · sector 89
DIVIDEND (yield)23 · sector 42

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $438.12 $592.64 +35%
Fresenius SE FRE €45.57 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, 5225 8.00 MYR 4.87 MYR −39%
Tenet Healthcare Corporation THC $262.06 $399.58 +52%
DaVita Inc DVA $183.72 $255.97 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹9,069 ₹2,908 −68%
Fresenius Medical Care AG FME €39.30 €71.28 +81%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "National HealthCare Corporation Fair Value". https://www.fairvalue-calculator.com/stock/NHC

Frequently asked questions

Is National HealthCare Corporation (NHC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $157.66 versus a price of $224.87, about −30% upside (overvalued).
What is the fair value of NHC?
Our model-based fair value for National HealthCare Corporation is $157.66 (as of Sep 23, 2026), built from audited fundamentals. The current price: $224.87.
What is the quality score of NHC?
National HealthCare Corporation has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for National HealthCare Corporation (NHC)?
Our model-based price target is the fair value of $157.66 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario $114.27, optimistic scenario $196.69. It is a calculation from audited fundamentals, not an analyst target.
What is the National HealthCare Corporation stock forecast for 2026?
Our models put fair value at $157.66, about −30% upside versus a price of $224.87 (overvalued). Cautious scenario $114.27, optimistic scenario $196.69. The calculation is refreshed regularly with new filings.
What is the revenue of National HealthCare Corporation (NHC)?
National HealthCare Corporation reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Sep 23, 2026).
Does National HealthCare Corporation pay a dividend?
National HealthCare Corporation currently shows a dividend yield of about 1.14% relative to its recent price (as of Sep 23, 2026).
What growth is priced into National HealthCare Corporation (NHC)?
For today's price to be fair in a discounted-cash-flow model, National HealthCare Corporation would have to grow free cash flow by +8.9 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of NHC use?
Our models discount National HealthCare Corporation at 8.9 %: a base by market capitalisation (mid), damped by beta 0.64, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For National HealthCare Corporation that is +8.9 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has National HealthCare Corporation (NHC) delivered so far?
Over the past 5 years revenue at National HealthCare Corporation grew +9.0 % a year. The price currently implies +8.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of National HealthCare Corporation (NHC) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into National HealthCare Corporation (+8.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of National HealthCare Corporation (NHC)?
The free-cash-flow yield on the price is 4.22 %: that much free cash flow National HealthCare Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of National HealthCare Corporation (NHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For National HealthCare Corporation it is $157.66 per share (as of Sep 23, 2026), against a price of $224.87. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is National HealthCare Corporation stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NHC trades above its calculated fair value: price $224.87, fair value $157.66, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NHC?
No. The price is what the market pays today ($224.87); the fair value is what the company's own numbers justify ($157.66). For National HealthCare Corporation the two are $67.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is National HealthCare Corporation worth?
The market values National HealthCare Corporation at about $3.5B (market capitalisation, as of Sep 23, 2026). Per share that is $224.87; our models calculate a fair value of $157.66 per share.
What do the bullish and bearish scenarios say about NHC?
Our models span a range for National HealthCare Corporation: cautious scenario $114.27, base $157.66, optimistic $196.69 per share (as of Sep 23, 2026, price $224.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NHC?
National HealthCare Corporation trades at a price-to-earnings ratio of 28.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $157.66 is built from several models across several years. Other multiples: PEG 0.8, P/B 3.3, P/S 2.3, EV/EBITDA 19.6.
What is the PEG ratio of NHC?
The PEG ratio of National HealthCare Corporation is 0.82 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of National HealthCare Corporation (NHC)?
Balance-sheet figures for National HealthCare Corporation (as of Sep 23, 2026): return on equity 12.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is NHC from its 52-week high?
National HealthCare Corporation trades at $224.87, about 5% below its 52-week high of $236.75 and 94% above the low of $116.05 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $157.66 is for.
Which stocks are comparable to National HealthCare Corporation?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is National HealthCare Corporation stock attractive at the current price?
The data as of Sep 23, 2026: price $224.87, calculated fair value $157.66 (−30%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NHC calculated?
We run National HealthCare Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $157.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. National HealthCare Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of National HealthCare Corporation (NHC)?
The closing price on Sep 23, 2026 was $224.87. Our model-based fair value is $157.66, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with National HealthCare Corporation right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($196.69). The favourable scenario is already priced in.
Where does the earnings growth of National HealthCare Corporation (NHC) come from?
Earnings per share at National HealthCare Corporation grew +6.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.6 %, EBIT margin +0.0 %, tax rate +2.0 %, residual (interest, one-offs) +0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of National HealthCare Corporation

How large is the market capitalisation of National HealthCare Corporation (NHC)?
The market capitalisation of National HealthCare Corporation is $3.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of National HealthCare Corporation (NHC)?
The price-to-sales ratio of National HealthCare Corporation is 2.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of National HealthCare Corporation (NHC)?
Earnings per share at National HealthCare Corporation are $7.87 (price ÷ EPS = P/E 28.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of National HealthCare Corporation (NHC)?
The dividend yield of National HealthCare Corporation is 1.1% (payout 32.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of National HealthCare Corporation (NHC)?
The net margin of National HealthCare Corporation is 7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of National HealthCare Corporation (NHC)?
The return on equity (ROE) of National HealthCare Corporation is 12.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of National HealthCare Corporation (NHC)?
On an EBIT basis the return on assets of National HealthCare Corporation is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of National HealthCare Corporation (NHC)?
The operating margin of National HealthCare Corporation is 8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at National HealthCare Corporation (NHC)?
Revenue at National HealthCare Corporation is growing +2.2% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at National HealthCare Corporation (NHC)?
Earnings per share at National HealthCare Corporation are growing +9.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does National HealthCare Corporation (NHC) hold?
National HealthCare Corporation holds more cash than debt, $23.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch National HealthCare Corporation in the live analysis

One click puts National HealthCare Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.